MAASTRO clinic
Maastricht, Limburg, 6229 ET, Netherlands
NCT Number: NCT01941303
As one of the few centers, MAASTRO also aggressively re-treats patients with recurrent non-small cell lung cancer. Even after primary radical treatment to high doses, re-irradiation (with concurrent chemotherapy) is also given in curative intent, thus again using high doses of radiation.
Publications on high-dose re-irradiation of lung cancer patients are scarce, and outcome and toxicity for patients treated in MAASTRO are unknown at present. This study will provide knowledge on benefit and risks of such a therapeutic approach.
Looking for future studies?
Notify MeAll sexes
Observational
Maastricht, Limburg, 6229 ET, Netherlands
MAASTRO clinic is a leader in the (individual) management of patients with lung cancer. This has resulted in major publications in the past on individualized (chemo)radiotherapy for (NSCLC) [van Baardwijk 2006 and 2010]. As one of the few centers, MAASTRO also aggressively re-treats patients with recurrent non-small cell lung cancer. Even after primary radical treatment to high doses, re-irradiation is also given in curative intent, thus again using high doses of radiation.
Publications on this topic are rare. Most reports address the results of palliative re-irradiation of NSCLC [Ebara 2007, Jackson 1987, Montebello 1993, Tada 2005]. The ones available on re-irradiation with curative intent used outdated techniques [Okamoto 2002, Wu 2003]. Only one recent publication has analyzed the results of 37 NSCLC patients of whom 9 were re-irradiated with at least 50 Gy using helical tomotherapy [Kruser in press].
The results of radical re-irradiation applying highly conformal radiation techniques within MAASTRO are unknown. This study will provide knowledge on benefit and risks of such a therapeutic approach. Furthermore, it may provide enough evidence to initiate a Phase II/III clinical trial for re-irradiation of NSCLC patients with curative intent.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Patients with advanced stage non-small cell lung cancer treated to higher doses of irradiation (i.e. EQD2>50Gy) twice: in the primary and recurrent setting.
Time frame: 1 year after radiotherapy
Measuring survival by checking if patients are alive.
Time frame: 1 year after radiotherapy
Measuring locoregional control by checking pt for progression
Time frame: 1 year after radiotherapy
Checking patients for progression
Time frame: 1 year after radiotherapy
Checking patients for pulmonary adverse events
Time frame: 1 year after radiotherapy
Checking patients for oesophageal adverse events
Time frame: 1 year after radiotherapy
Checking patients fortoxicity which causes problems with regard to radiotherapy-dose or is otherwise burdensome
Maastricht Radiation Oncology
Other
Radical Re-irradiation of Recurrent NSCLC - Analysis of Outcome and Toxicity.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02718066
Adenocarcinoma, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial DetailsNCT05348668
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hefei, Anhui, China
View Trial DetailsNCT04702009
Advanced Lung Carcinoma, Bronchial Neoplasms
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06477055
Bronchial Neoplasms, Carcinoma, Bronchogenic
Changsha, Hunan, China
View Trial Details